Anthropometric measurements and diabetes mellitus: Clues to the "pathogenic" and "protective" potential of adipose tissue

Metabolic Syndrome and Related Disorders

Volumn 8, Issue 4, 2010, Pages 307-315

  Bays, Harold E ^a   Fox, Kathleen M ^b   Grandy, Susan ^c  

^a LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER   (United States)

^b Strategic Healthcare Solutions LLC   (United States)

^c ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOSE TISSUE; ADULT; ANTHROPOMETRIC PARAMETERS; ARTICLE; BODY HEIGHT; BODY MASS; BODY WEIGHT; CONTROLLED STUDY; FEMALE; HUMAN; INTRAABDOMINAL FAT; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; SELF REPORT; WAIST CIRCUMFERENCE; WAIST HIP RATIO;

ADIPOSE TISSUE; ANTHROPOMETRY; BODY MASS INDEX; COHORT STUDIES; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; HEALTH SURVEYS; HIP; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; QUESTIONNAIRES; SOCIOECONOMIC FACTORS; WAIST CIRCUMFERENCE; WAIST-HIP RATIO;

EID: 77955582922     PISSN: 15404196     EISSN: None     Source Type: Journal    
DOI: 10.1089/met.2009.0089     Document Type: Article

References (70)

1. "Sick fat," metabolic disease, and atherosclerosis. Am J Med 2009;122(1 Suppl):S26-S37.
2. Bays HE, Chapman RH, Grandy S., The relationship of body mass index to diabetes mellitus, hypertension,and dyslipidae- mia: Comparison of data from two national surveys. Int J Clin Pract 2007;61:737-747.
3. Artham SM, Lavie CJ, Milani RV, Ventura HO. The obesity paradox: impact of obesity on the prevalence and prognosis of cardiovascular diseases. Postgrad Med 2008;120:34-41.
4. Orpana HM, Berthelot JM, Kaplan MS, Feeny DH, McFarland B, Ross NA., BMI,and Mortality: Results From a National Longitudinal Study of Canadian Adults. Obesity (Silver Spring) 2009, doi:10.1038/oby.2009.191.
5. Hamdy O, Porramatikul S, Al-Ozairi E. Metabolic obesity: The paradox between visceral and subcutaneous fat. Curr Diabetes Rev 2006;2:367-373.
6. McCarty MF. A paradox resolved: The postprandial model of insulin resistance explains why gynoid adiposity appears to be protective. Med Hypotheses 2003;61:173-176.
7. Bays H, Ballantyne C. Adiposopathy: Why do adiposity and obesity cause metabolic disease? Future Lipidol 2006;1:389-420.
8. Bays HE, Gonzalez-Campoy JM, Bray GA, Kitabchi AE, Bergman D, Schorr AB, Rodbard HW, Henry RR. The pathogenic potential of adipose tissue and the metabolic consequences of adipo-cyte hypertrophy and increased visceral adiposity. Expert Rev Cardiovasc Ther 2008;6:343-368.
9. Bluher M. Adipose tissue dysfunction in obesity. Exp Clin Endocrinol Diabetes 2009;117:241-250.
10. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC Jr, Spertus JA, Costa F. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005;112:2735-2752.
11. Bays H. Adiposopathy, metabolic syndrome, quantum physics, general relativity, chaos and the Theory of Everything. Expert Rev Cardiovasc Ther 2005;3:393-404.
12. Bays H, Abate N, Chandalia M. Adiposopathy: Sick fat causes high blood sugar, high blood pressure, and dyslipidemia. Future Cardiol 2005;1:39-59.
13. Kahn R, Buse J, Ferrannini E, Stern M. The metabolic syndrome: Time for a critical appraisal: Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2005;28:2289-2304.
14. Reaven G. The metabolic syndrome or the insulin resistance syndrome? Different names, different concepts, and different goals. Endocrinol Metab ClinNAm 2004;33:283-303.
15. Reaven GM. The metabolic syndrome: is this diagnosis necessary? Am J Clin Nutr 2006;83:1237-1247.
16. Vague J. La differentiation sexuelle, facteur determinant des formes de l'obesite. Presse Med 1947;30:339-340.
17. Stolk RP, Meijer R, Mali WP, Grobbee DE, van der Graaf Y. Ultrasound measurements of intraabdominal fat estimate the metabolic syndrome better than do measurements of waist circumference. Am J Clin Nutr 2003;77:857-860.
18. Bays H, Dujovne CA. Adiposopathy is a more rational treatment target for metabolic disease than obesity alone. Curr Atheroscler Rep 2006;8:144-156.
19. International Diabetes Federation. The IDF consensus worldwide definition of the metabolic syndrome. 2006. . idf.org/webdata/docs/MetS-def-update2006. pdf/. Accessed September 25, 2009.
20. Klein S, Allison DB, Heymsfield SB, Kelley DE, Leibel RL, Nonas C, Kahn R. Waist Circumference and Cardiometabolic Risk: A Consensus Statement from Shaping America's Health: Association for Weight Management and Obesity Prevention; NAASO, the Obesity Society; the American Society for Nutrition; and the American Diabetes Association. Obesity (Silver Spring) 2007;15:1061-1067.
21. Bays H, Blonde L, Rosenson R. Adiposopathy: How do diet, exercise, weight loss and drug therapies improve metabolic disease? Expert Rev Cardiovasc Ther 2006;4:871-895.
22. Porter SA, Massaro JM, Hoffmann U, Vasan RS., O'Donnell CJ, Fox CS. Abdominal subcutaneous adipose tissue: A protective fat depot? Diabetes Care 2009;32:1068-1075.
23. Narumi H, Yoshida K, Hashimoto N, Umehara I, Funabashi N, Yoshida S, Komuro I. Increased subcutaneous fat accumulation has a protective role against subclinical atherosclerosis in asymptomatic subjects undergoing general health screening. Int J Cardiol 2009;135:150-155.
24. Bays HE, Gonzalez-Campoy JM, Henry RR, Bergman DA, Kitabchi AE, Schorr AB, Rodbard HW. Is adiposopathy (sick fat) an endocrine disease? Int J Clin Pract 2008;62:1474-1483.
25. Lissner L, Bjorkelund C, Heitmann BL, Seidell JC, Bengtsson C. Larger hip circumference independently predicts health and longevity in a Swedish female cohort. Obes Res 2001;9:644-646.
26. Seidell JC, Han TS, Feskens EJ, LeanME. Narrow hips and broad waist circumferences independently contribute to increased risk of non-insulin-dependent diabetes mellitus. J Intern Med 1997;242:401-406.
27. Molarius A, Seidell JC, Sans S, Tuomilehto J, Kuulasmaa K. Varying sensitivity of waist action levels to identify subjects with overweight or obesity in 19 populations of the WHO MONICA Project. JClin Epidemiol 1999;52:1213-1224.
28. Vazquez G, Duval S, Jacobs DR Jr, Silventoinen K. Comparison of body mass index, waist circumference, and waist/hip ratio in predicting incident diabetes: A meta-analysis. Epidemiol Rev 2007;29:115-128.
29. Bays HE, Bazata DD, Clark NG, Gavin JR III, Green AJ, Lewis SJ, Reed ML, Stewart W, Chapman RH, Fox KM, Grandy S. Prevalence of self-reported diagnosis of diabetes mellitus and associated risk factors in a national survey in the US population: SHIELD (Study to Help Improve Early evaluation and management of risk factors Leading to Diabetes) . BMC Public Health 2007;7:277.
30. Mason C, Katzmarzyk PT. Effect of the site of measurement of waist circumference on the prevalence of the metabolic syndrome. Am J Cardiol 2009;103:1716-1720.
31. Mason C, Katzmarzyk PT. Variability in waist circumference measurements according to anatomic measurement sites. Obesity 2009;17:1789-11785
32. Spencer EA, Appleby PN, Davey GK, Key T J. Validity of self-reported height and weight in 4808 EPIC-Oxford participants . Public Health Nutr 2002;5:561-565.
33. Vila-Funes JA, Gutierrez-Robledo LM, Ponce De Leon Rosales S. Validity of height and weight self-report in Mexican adults: Results from the national health and aging study. J Nutr Health Aging 2004;8:355-361.
34. Spencer EA, Roddam AW., Key, T. J. Accuracy of self-reported waist and hip measurements in 4492 EPIC-Oxford participants. Public Health Nutr 2004;7:723-727.
35. The Diabetes Prevention Program Research Group. Relationship of body size and shape to the development of diabetes in the diabetes prevention program. Obesity (Silver Spring) 2006;14:2107-2117.
36. Ryan MC, Fenster Farin HM, Abbasi F, Reaven GM. Comparison of waist circumference versus body mass index in diagnosing metabolic syndrome and identifying apparently healthy subjects at increased risk of cardiovascular disease. Am J Cardiol 2008;102:40-46.
37. Abate N, Garg A, Peshock RM, Stray-Gundersen J, ms-Huet B, Grundy SM. Relationship of generalized and regional adiposity to insulin sensitivity in men with NIDDM. Diabetes 1996;45:1684-1693.
38. Brooks N, Layne JE, Gordon PL, Roubenoff R, Nelson ME, Castaneda-Sceppa C. Strength training improves muscle quality and insulin sensitivity in Hispanic older adults with type 2 diabetes. Int JMed Sci 2007;4:19-27.
39. Lucas JW, Schiller JS, Benson V. Summary health statistics for U.S. adults: National Health Interview Survey, 2001. Vital Health Stat 2004;10:1-134.
40. Bazata DD, Robinson JG, Fox KM, Grandy S. Affecting behavior change in individuals with diabetes: findings from the Study to Help Improve Early Evaluation and Management of Risk Factors Leading to Diabetes (SHIELD). Diabetes Educ 2008;34:1025-1036.
41. Wajchenberg BL. Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. Endocr Rev 2000;21:697-738.
42. Baker AR, Silva NF, Quinn DW, Harte AL, Pagano D, Bonser RS, Kumar S, McTernan PG. Human epicardial adipose tissue expresses a pathogenic profile of adipocytokines in patients with cardiovascular disease. Cardiovasc Diabetol 2006;5:1.
43. Higuchi ML, Gutierrez PS, Bezerra HG, Palomino SA, Aiello VD, Silvestre JM, Libby P, Ramires JA. Comparison between adventitial and intimal inflammation of ruptured and nonrup-tured atherosclerotic plaques in human coronary arteries. Arq Bras Cardiol 2002;79:20-24.
44. Engeli S, Negrel R, Sharma AM. Physiology and pathophysiology of the adipose tissue renin-angiotensin system. Hypertension 2000;35:1270-1277.
45. Mazurek T, Zhang L, Zalewski A, Mannion JD, Diehl JT, Arafat H, Sarov-Blat L, O'Brien S, Keiper EA, Johnson AG, Martin J, Goldstein BJ, Shi Y. Human epicardial adipose tissue is a source of inflammatory mediators. Circulation 2003;108:2460-2466.
46. Stenvinkel P. Leptin and blood pressure-is there a link? Nephrol Dial Transplant 2000;15:1115-1117.
47. Franks PW, Brage S, Luan J, Ekelund U, Rahman M, Farooqi IS, Halsall I, O'Rahilly S, Wareham NJ. Leptin predicts a worsening of the features of the metabolic syndrome independently of obesity. Obes Res 2005;13:1476-1484.
48. Bravo PE, Morse S, Borne DM, Aguilar EA, Reisin E. Leptin and hypertension in obesity. Vasc Health Risk Manag 2006;2:163-169.
49. Brook RD, Bard RL, Bodary PF, Eitzman DT, Rajagopalan S, Sun Y, DePaoli AM. Blood pressure and vascular effects of leptin in humans. Metab Syndr Relat Disord 2007;5:270-274.
50. Van Harmelen V, Reynisdottir S, Eriksson P, Thorne A, Hoffstedt J, Lonnqvist F, Arner P. Leptin secretion from subcutaneous and visceral adipose tissue in women. Diabetes 1998;47:913-917.
51. Couillard C, Mauriege P, Imbeault P, Prud'homme D, Nadeau A, Tremblay A, Bouchard C, Despres JP. Hyperleptinemia is more closely associated with adipose cell hypertrophy than with adipose tissue hyperplasia. Int J Obes Relat Metab Disord 2000;24:782-788.
52. Johnson JA, Fried SK, Pi-Sunyer FX, Albu JB. Impaired insulin action in subcutaneous adipocytes from women with visceral obesity. Am J Physiol Endocrinol Metab 2001;280:E40-E49.
53. Bays H, Mandarino L, DeFronzo RA. Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach. J Clin Endocrinol Metab 2004;89:463-478.
54. Folsom AR, Kushi LH, Anderson KE, Mink PJ, Olson JE, Hong CP, Sellers TA, Lazovich D, Prineas RJ. Associations of general and abdominal obesity with multiple health outcomes in older women: the Iowa Women's Health Study. Arch Intern Med 2000;160:2117-2128.
55. Meisinger C, Doring A, Thorand B, Heier M, Lowel H. Body fat distribution and risk of type 2 diabetes in the general population: Are there differences between men and women? The MONICA/KORA Augsburg cohort study. Am J Clin Nutr 2006;84:483-489.
56. Wannamethee SG, Shaper AG, Morris RW, Whincup PH. Measures of adiposity in the identification of metabolic abnormalities in elderly men. Am J Clin Nutr 2005;81:1313-1321.
57. Wang Y, Rimm EB, Stampfer MJ, Willett WC, Hu FB. Comparison of abdominal adiposity and overall obesity in predicting risk of type 2 diabetes among men. Am J Clin Nutr 2005;81:555-563.
58. Mamtani MR, Kulkarni HR. Predictive performance of anthro-pometric indexes of central obesity for the risk of type 2 diabetes. Arch Med Res 2005;36:581-589.
59. Gelber RP, Gaziano JM, Orav EJ, Manson JE, Buring JE, Kurth T. Measures of obesity and cardiovascular risk among men and women. JAm Coll Cardiol 2008, 52:605-615.
60. Mojiminiyi OA, A1 Mulla F, Abdella NA. Which obesity index best explains the link between adipokines, coronary heart disease risk and metabolic abnormalities in type 2 diabetes mellitus? Med Princ Pract 2009;18:123-129.
61. Haap M, Siewecke C, Thamer C, Machann J, Schick F, Haring HU, Szeimies RM, Stumvoll M. Multiple symmetric lipomatosis: A paradigm of metabolically innocent obesity? Diabetes Care 2004;27:794-795.
62. Krotkiewski M, Bjorntorp P, Sjostrom L, Smith U. Impact of obesity on metabolism in men and women. Importance of regional adipose tissue distribution. J Clin Invest 1983;72:1150-1162.
63. Lemieux I. Energy partitioning in gluteal-femoral fat: does the metabolic fate of triglycerides affect coronary heart disease risk? Arterioscler Thromb Vasc Biol 2004;24:795-797.
64. Pigeon E, Couillard E, Tremblay A, Bouchard C, Weisnagel S, Joanisse DR. Mid-thigh subcutaneous adipose tissue and glucose tolerance in the Quebec Family Study. Obesity Facts 2008;1:310-318.
65. Bray GA, Jablonski KA, Fujimoto WY, Barrett-Connor E, Haffner S, Hanson RL, Hill JO, Hubbard V, Kriska A, Stamm E, Pi-Sunyer FX. Relation of central adiposity and body mass index to the development of diabetes in the Diabetes Prevention Program. Am J Clin Nutr 2008;87:1212-1218.
66. Bays HE, Chapman RH, Fox KM, Grandy S. Comparison of self-reported survey (SHIELD) versus NHANES data in estimating prevalence of dyslipidemia. Curr Med Res Opin 2008;24:1179-1186.
67. Hariri S, Yoon PW, Qureshi N, Valdez R, Scheuner MT, Khoury MJ. Family history of type 2 diabetes: a population-based screening tool for prevention? Genet Med 2006:8:102-108.
68. Falk DE, Yi HY, Hiller-Sturmhofel S. An epidemiologic analysis of co-occurring alcohol and tobacco use and disorders: findings from the National Epidemiologic Survey on Alcohol and Related Conditions. Alcohol Res Health 2006;29:162-171.
69. Hirschfeld RM, Calabrese JR, Weissman MM, Reed M, Davies MA, Frye MA, Keck PE Jr, Lewis L, McElroy SL, McNulty JP, Wagner KD. Screening for bipolar disorder in the community. J Clin Psychiatry 2003;64:53-59.
70. Stewart WF, Lipton RB, Celentano DD, Reed ML. Prevalence of migraine headache in the United States. Relation to age, income, race, and other sociodemographic factors. JAMA 1992;267:64-69.